caa a22 4500 469121831 CHVBK 20180323133141.0 cr unu---uuuuu 170328e19920401xx s 000 0 eng 10.1007/BF02244823 doi (NATIONALLICENCE)springer-10.1007/BF02244823 Benzodiazepine-induced sedation and cortisol suppression [Elektronische Daten] A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers [P. Christensen, A. Lolk, L. Gram, P. Kragh-Sørensen] The sedative and cortisol suppressing properties of oxazepam (45 and 60 mg) and nitrazepam (10 and 15 mg) were examined in eight healthy male subjects. The most clear differences between oxazepam and nitrazepam were those seen with respect to the time course and until maximal effect (Tmax) of the different measurements. Nitrazepam showed maximal sedation after 1 h, maximal benzodiazepine level (RRA), and reaction time prolongation after 2 h, and maximal cortisol suppression after 3 h. Oxazepam showed maximal sedation after 2 h, maximal benzodiazepine levels, reaction time prolongation and cortisol suppression after 3 h. After administration of oxazepam (both doses) a transient return to baseline levels of cortisol was demonstrated. Whereas the degree of sedation correlated significantly within drug groups with the concurrent benzodiazepine levels, the Tmax of sedation was recorded 1 h earlier than the peak blood concentration (RRA) for both nitrazepam and oxazepam. The time course for cortisol suppression for the two compounds differed clearly from the other measurements and was not related to the peak blood concentration. Springer-Verlag, 1992 Plasma cortisol nationallicence Suppression nationallicence Oxazepam nationallicence Nitrazepam nationallicence Sedation nationallicence Reaction times nationallicence Christensen P. Department of Clinical Pharmacology, Odense University, School of Medicine, DK-Odense, Denmark aut Lolk A. Department of Psychiatry, Odense University, School of Medicine, DK-Odense, Denmark aut Gram L. Department of Clinical Pharmacology, Odense University, School of Medicine, DK-Odense, Denmark aut Kragh-Sørensen P. Department of Psychiatry, Odense University, School of Medicine, DK-Odense, Denmark aut Psychopharmacology Springer-Verlag 106/4(1992-04-01), 511-516 0033-3158 106:4<511 1992 106 213 https://doi.org/10.1007/BF02244823 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244823 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Christensen P. Department of Clinical Pharmacology, Odense University, School of Medicine, DK-Odense, Denmark aut NATIONALLICENCE 700 1- Lolk A. Department of Psychiatry, Odense University, School of Medicine, DK-Odense, Denmark aut NATIONALLICENCE 700 1- Gram L. Department of Clinical Pharmacology, Odense University, School of Medicine, DK-Odense, Denmark aut NATIONALLICENCE 700 1- Kragh-Sørensen P. Department of Psychiatry, Odense University, School of Medicine, DK-Odense, Denmark aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106/4(1992-04-01), 511-516 0033-3158 106:4<511 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer